FAMY LIFE SCIENCES

Viatris buys Taparias' eyecare business for Rs 2,460 crore

The ophthalmology portfolio consists of six new chemical entities (NCEs or molecules) that are under phase 3 trials and will be developed further by the Vitaris. The remaining oncology and dermatology business will be demerged into a new entity named Famy Pharma.